Completed OBSERVATIONAL NCT05318391

Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Sponsor: Shanghai Minhang Central Hospital

Conditions Gene Expression Profiling Lymphoma, Large B-Cell, Diffuse

Updated 3 times since 2022 Last updated: Mar 31, 2022 Started: Apr 14, 2021 Primary completion: Jan 30, 2022 Completion: Mar 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Gene Expression Profiling and Lymphoma, Large B-Cell, Diffuse and is currently completed. Shanghai Minhang Central Hospital leads this study, which shows 3 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2022 — Jul 2024 [monthly]

Completed

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Minhang Central Hospital
Shanghai Zhongshan Hospital
Wuxi People's Hospital

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China